Bio4Dreams Raises €2.4 Million in its Equity Crowdfunding Round

Bio4Dreams, a certified incubator of very early-stage innovative startups dedicated to Life Sciences, has recently closed an equity crowdfunding round raising €2.4 million.

The campaign, launched on Crowdfundme, involved 122 investors, all, evidently, with high financial means, as the minimum investment was €10,000.

Read more about the latest crowdfunding campaign launched by the Bio4Dreams incubator and find the latest financial news of the day with the Born2Invest mobile app.

Bio4Dreams – An Italian incubator dedicated to life science

Bio4Dreams operates by incubating startups operating in the Life Science segments (pharmaceutical industry, biotech, diagnostics, e-health, and medical devices) to which it offers expertise and networks, as well as making targeted investments in the most promising ones.

The issuer currently owns a diversified portfolio of 12 investee startups or SMEs that registers a 6x appreciation between 2018 and 2022, with a total estimated present value of about 58 million, of which 8 million are the shares held by Bio4Dreams.

In less than 5 years of operation, the company has built an ecosystem across 11 locations in national territories and 6 international areas. And, to date, more than 1,200 projects have been evaluated and 38 startups and SMEs incubated, including 12 investees.

The goal of Bio4Dreams, is to industrialize the innovation process, creating a world-class ecosystem capable of structuring the development path of a new venture, from idea to market.

The ecosystem includes internationally renowned industrial partners such as Janssen Cilag S.p.A. – Johnson & Johnson Group, Chiesi Farmaceutici, Dompé Farmaceutici, MSD and Dedalus, and scientific partners such as EO – European Institute of Oncology (Milan) and I. R.C.C.S. Istituto Ortopedico Galeazzi (Milan), Ca’ Foscari University (Venice), University of Genoa (Genoa), University of Pécs (Pécs – Hungary) and Jagiellonian University (Krakow – Poland).

The main strategic projects of Bio4Dreams

Among the activities of Bio4Dreams, the “Innovation CircleTM” and “SharedLabsTM” projects assume particular importance.

Innovation CircleTM represents a new approach to technology transfer in the Life Sciences that takes the form of a physical and virtual space in which actors from the innovation chain, technology transfer, industry, and finance are directly involved to promote startups by pooling resources, expertise, and networks. The project is mainly delineated around five thematic areas: therapeutics, diagnostics, medical devices, regenerative medicine, and AI.

SharedLabsTM are shared research labs, organized and equipped by function, which can be used on-demand by startups for necessary scientific validation activities. The spaces are not physically divided among the startups that will use them but are organized and equipped in modules by research scope and function: sensors, biomaterials, molecular biology, cell biology, chemistry and biochemistry.

The Labs are also characterized by a very high degree of integrability: the startups themselves, should they be equipped with particular equipment, can share these technologies through commercial agreements, thus reducing any downtime and redistributing costs. The project is based at MIND – Milano Innovation District (former Expo Area), the new international citadel of innovation.

A significant portion of the capital raised will be used to invest in an additional 12 new startups as well as in the startups and SMEs already involved (follow-on).

In addition, investments have already been made in innovation hubs such as MIND – Milano Innovation District that needs expansion both of dedicated office space and shared research labs for startups and for the development of Bio4Dreams’ corporate structure.

Finally, investments are planned in internationalization activities targeted mainly in the United States and Eastern Europe.

__

(Featured image by QuinceCreative via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.